Register Now - Every Drop Matters: Reducing Product Loss in Sterile Filtration
News|Podcasts|July 7, 2026

The BioPharm Brief: Smarter Targeting, Myeloid Engagers, Neuron Replacement

Listen
0:00 / 0:00

Today's BioPharm Brief explores three different ways biopharma companies are advancing precision medicine, from next generation bispecific antibody drug conjugates and myeloid engager immunotherapy to stem cell derived neuron replacement for Parkinson's disease.

Welcome to The BioPharm Brief, your daily snapshot of developments shaping the biopharmaceutical industry. Today, we're looking at three distinct strategies designed to improve precision in treating disease, from combining cutting edge antibody technologies to harnessing the innate immune system against cancer and replacing neurons lost in Parkinson's disease.

Our first story focuses on the growing convergence of two powerful oncology platforms. Biocytogen and Whitehawk Therapeutics have entered a global collaboration to develop bispecific antibody drug conjugates by combining complementary discovery and drug delivery technologies. The partnership pairs Biocytogen's RenLite bispecific antibody platform with Whitehawk's proprietary linker payload and bioconjugation technology, with the goal of creating therapies that more precisely target tumors while improving the therapeutic index. The collaboration reflects growing industry interest in integrating multiple antibody engineering approaches into a single therapeutic format.

Next, LTZ Therapeutics has received FDA investigational new drug clearance for LTZ-232, a first in class myeloid engager bispecific antibody for patients with EpCAM positive colorectal cancer. Unlike many immunotherapies that primarily activate T cells, LTZ-232 is designed to recruit and activate myeloid cells, including macrophages, to attack tumor cells while minimizing inflammatory cytokine release. The Phase 1 study will evaluate the investigational therapy in patients with advanced or metastatic colorectal cancer and represents another example of developers expanding beyond traditional T cell based immunotherapy strategies.

Finally, Kenai Therapeutics has completed enrollment in its phase 1 REPLACE clinical trial evaluating RNDP-001, an induced pluripotent stem cell derived dopaminergic neuron therapy for Parkinson's disease. The investigational treatment is designed to replace the dopamine producing neurons that progressively degenerate in Parkinson's, potentially addressing the underlying cause of motor symptoms rather than simply managing them. Completion of enrollment marks an important milestone as researchers continue evaluating the safety, tolerability, and early evidence of cell survival following transplantation.

Thanks for listening to The BioPharm Brief. For analysis and expert insights, please visit BioPharmInternational.com.

Key Takeaways

  • Bispecific antibody drug conjugates continue to gain momentum as companies combine complementary technologies to improve precision oncology.
  • Myeloid cell engagement is emerging as a promising alternative immunotherapy strategy for solid tumors.
  • Cell replacement therapies for neurodegenerative diseases continue to advance, with Parkinson's disease remaining a leading focus for regenerative medicine.

Related to this article

The BioPharm Brief: Long-Term Survival Data for a PD-L1/4-1BB Bispecific, Celldex Exits Atopic Dermatitis, and a Fc-Fusion GLP-1 Goes Global
Leads Biolabs details survival data and 2027 ADC combination plans for its PD-L1/4-1BB bispecific opamtistomig, Celldex Therapeutics ends its atopic dermatitis program for anti-KIT antibody barzolvolimab after a phase 2 miss, and Innogen licenses its Fc-fusion GLP-1 receptor agonist efsubaglutide alfa to Arcera Life Sciences for international markets.
The BioPharm Brief: A Matrix-Targeting ADC in Head and Neck Cancer, an RNAi Approval in Myasthenia Gravis, and AbbVie Bets on AND-Gated Bispecifics
Pyxis Oncology’s EDB+FN-targeting ADC micvotabart pelidotin shows a 39% confirmed response rate in previously treated head and neck cancer, FDA approves Regeneron’s cemdisiran (Livsayis), an RNAi therapy Regeneron licensed from Alnylam Pharmaceuticals, as the first RNAi therapy for generalized myasthenia gravis, and AbbVie partners with DISCO Pharmaceuticals on AND-gated bispecifics for solid tumors.
The BioPharm Brief: A First for Streamlined Biosimilar Approval, a Head-to-Head Bispecific Trial in Wet AMD, and In Vivo KIR-CAR T
Biocon’s pertuzumab biosimilar Pebrilzo becomes the first biosimilar approved under EMA’s tailored clinical approach, Visara doses the first patient in a phase 2b trial comparing its VEGF-A/ANG-2 bispecific VIS-101 with aflibercept in wet AMD, and Verismo Therapeutics licenses Stanford’s PACK-IT technology for in vivo KIR-CAR T therapies.
The BioPharm Brief: FDA’s Fast-Track Pilot Reportedly Stalls, a Long-Acting Bispecific for Atopic Dermatitis, and a Twice-Yearly Obesity Approach
FDA has reportedly shelved its Commissioner’s National Priority Voucher pilot and paused publishing complete response letters, Zai Lab’s IL-13/IL-31Rα bispecific ZL-1503 shows a 40- to 50-day half-life that points to dosing every 12 weeks, and Wave Life Sciences reports 1-year INLIGHT data for its INHBE-silencing siRNA WVE-007 in obesity.
The BioPharm Brief: An AI-Designed Multibody ADC Enters the Clinic, Blackstone Backs Pfizer’s Monthly GLP-1, and enGene Readies a Bladder Cancer BLA
FDA clears the IND for Biolojic Design’s BD200, an AI-designed Trop2/Nectin-4 multibody ADC; Blackstone Life Sciences agrees to provide Pfizer up to $1.5 billion to develop its monthly GLP-1 receptor agonist berobenatide; and enGene Therapeutics plans a year-end BLA for detalimogene voraplasmid in BCG-unresponsive non-muscle invasive bladder cancer.